Michel Mirowski and the beginning of a new era of fighting sudden arrhythmic death.

Prior to the implantable cardioverter-defibrillator (ICD), life-threatening ventricular arrhythmias were treated using anti-arrhythmic drugs. The concept of an implantable defibrillator to prevent sudden arrhythmic death was first published by Michel Mirowski in 1970. Despite critical opinions by leading physicians, Michel Mirowski continued development of his vision.

The story of … a lead.

The totally transvenous implantable defibrillator lead, conceived by Mirowski and Mower 45 years ago, is irrevocably related to the wide acceptance of this therapy. It paved the way for the era for non-thoracotomy implantation. This paper covers the most important details of the evolution--over this 45-year period--of the original (ENDOTAK) transvenous ICD lead and subsequent iterations.

Confirmation of the cellular targets of benomyl and rapamycin using next-generation sequencing of resistant mutants in S. cerevisiae.

Investigating the mechanisms of action (MOAs) of bioactive compounds and the deconvolution of their cellular targets is an important and challenging undertaking. Drug resistance in model organisms such as S. cerevisiae has long been a means for discovering drug targets and MOAs.

20 years of cardiac resynchronization therapy.

Cardiac resynchronization therapy (CRT) is an accepted treatment for patients with heart failure (HF), impaired left ventricular (LV) function, and a wide QRS complex. It has been revolutionary for patients with advanced HF whose only previous option was cardiac transplantation, and it is now a realistic option for patients with mild HF. The development of CRT also has united the previously disparate cardiological subspecialties of electrophysiology and HF.